<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02630875</url>
  </required_header>
  <id_info>
    <org_study_id>A4250-003</org_study_id>
    <nct_id>NCT02630875</nct_id>
  </id_info>
  <brief_title>A4250, an IBAT Inhibitor in Pediatric Cholestasis</brief_title>
  <official_title>An Exploratory Phase II Study to Demonstrate the Safety and Efficacy of A4250 in Children With Cholestatic Pruritus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albireo</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Albireo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate A4250 (IBATinhibitor) as a treatment option in pediatric patients
      with chronic cholestasis with main emphasis on safety evaluation and on effects on pruritus
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aims of this Phase II exploratory study in patients treated with A4250 due to
      cholestasis induced pruritus are to:

        -  Assess the safety and tolerability of A4250, orally administered first as a single dose
           and then during a four week treatment period, as determined by the occurrence of
           treatment-emergent SAEs

        -  Explore changes in serum total bile acids after a four week treatment period

      Secondary safety aims include assessment of the safety and tolerability of A4250, orally
      administered first as a single dose and then during a four week treatment period, as
      determined by the occurrence of treatment-emergent AEs and changes in safety parameters
      including laboratory tests and vital signs

      Secondary efficacy aims are to:

        -  Demonstrate the efficacy of A4250, orally administered during a four week treatment
           period, on liver biochemistry variables and on pruritus parameters

        -  Evaluate the pharmacokinetic properties of A4250 orally administered first as a single
           dose and then after a four week treatment period

        -  Evaluate changes in VAS-itching score after a four week treatment period
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">March 17, 2017</completion_date>
  <primary_completion_date type="Actual">March 17, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AE evaluation</measure>
    <time_frame>4 wks</time_frame>
    <description>Treatment-emergent SAEs Adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bile acid changes</measure>
    <time_frame>4 weeks</time_frame>
    <description>Evaluation of bile acids</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Pediatric Cholestasis</condition>
  <arm_group>
    <arm_group_label>A4250 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose I</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A4250 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A4250 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A4250 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A4250 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A4250 6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A4250</intervention_name>
    <description>A4250</description>
    <arm_group_label>A4250 1</arm_group_label>
    <arm_group_label>A4250 2</arm_group_label>
    <arm_group_label>A4250 3</arm_group_label>
    <arm_group_label>A4250 4</arm_group_label>
    <arm_group_label>A4250 5</arm_group_label>
    <arm_group_label>A4250 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of pruritus due to chronic cholestasis based on history and investigator
             judgment. This will include but will not be restricted to patients with Progressive
             familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS), Biliary Atresia
             and Sclerosing Cholangitis

        Exclusion Criteria:

          -  Any condition that in the opinion of the investigator constitutes a risk for the
             patient or a contraindication for participation and completion of the study, or could
             interfere with study objectives, conduct, or evaluations

          -  Clinical or biochemical signs of decompensated liver disease

          -  Liver transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mats Ekelund, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Albireo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henrik Arnell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Pediatric and Adolescent Medicine Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Hepatology and Liver Transplantation, University Hospitals of Paris-Sud</name>
      <address>
        <city>Paris</city>
        <state>Orsay</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatric Gastroenterology Hepatology-Nutrition, Necker-Enfants maladies hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Gastroenterology and Hepatology, Pediatric Surgery, Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology/Hepatology, University Hospital for Children and Adolescents</name>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henrik Arnell</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2015</study_first_submitted>
  <study_first_submitted_qc>December 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2015</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

